Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma.
Lipika GoyalFunda Meric-BernstamAntoine HollebecqueJuan W ValleChigusa MorizaneThomas B KarasicThomas A AbramsJunji FuruseRobin Kate KelleyPhilippe A CassierHeinz-Josef KlümpenHeung-Moon ChangLi-Tzong ChenJosep TaberneroDo-Youn OhAmit MahipalMarkus MoehlerEdith P MitchellYoshito KomatsuKunihiro MasudaDaniel AhnRobert S EpsteinAbdel-Baset HalimYao FuTehseen SalimiVolker WacheckYaohua HeMei LiuKarim A BenhadjiJohn A Bridgewaternull nullPublished in: The New England journal of medicine (2023)
fusion or rearrangement-positive intrahepatic cholangiocarcinoma, the use of futibatinib, a covalent FGFR inhibitor, led to measurable clinical benefit. (Funded by Taiho Oncology and Taiho Pharmaceutical; FOENIX-CCA2 ClinicalTrials.gov number, NCT02052778.).
Keyphrases